CD274 and non-small cell lung carcinoma: Immune checkpoint inhibitors (ICIs), such as those targeting PD-1, PD-L1, and CTLA-4, have emerged as promising therapies for locally advanced and metastatic cancers [6,7,8,9,10,11,12,13,14], including NSCLC [15,16,17,18,19,20].